RxDoctor Payments Data

Wendy Hanner, APRN

Family · Lonoke, ARNPI 1083297741

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 32.0% of the total. That places this record below the midpoint for family clinicians in AR, where the typical reported total is $365.

$182in general payments, 2019–2025

Across 11 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$58
  • AstraZeneca$34
  • Organon$18
  • Exact Sciences$16
  • Pfizer$14
  • Sunovion Pharmaceuticals Inc.$14
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$182 in reported general payments places this provider in the 35th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$706
Medicare patients
33
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$47,416
JardianceEmpagliflozin46$32,567
OzempicSemaglutide32$31,312
EliquisApixaban30$20,618
TrulicityDulaglutide17$17,106
SymbicortBudesonide/Formoterol Fumarate21$4,890
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,588
Albuterol Sulfate HfaAlbuterol Sulfate144$3,051
Gabapentin185$2,499
Atorvastatin Calcium252$2,320
BreynaBudesonide/Formoterol Fumarate13$2,077
Novolog FlexpenInsulin Aspart14$1,661
Diclofenac Sodium105$1,467
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,349
Omeprazole102$1,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$20,61830 claims
AstraZenecaSymbicort$34$4,89021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,103 family providers in Arkansas.

Other family in Lonoke

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →